Tarapeutics Pharmaceutical Science

Tarapeutics Pharmaceutical Science is a clinical-stage biotechnology company based in Bengbu, China, dedicated to the discovery and development of innovative small molecule therapies for oncology and other chronic diseases. The company utilizes advanced drug delivery platforms to create precision medicines that target key signaling pathways and genetic drivers of cancer, including FLT3, CDK9, and the CLK/DYRK kinase families. Its clinical pipeline features several promising candidates, most notably HYML-122, which is in Phase 2 development for acute myeloid leukemia, and TR115, currently being evaluated in Phase 1 trials for non-Hodgkin's lymphoma and solid tumors. Tarapeutics maintains strong ties with academic institutions like the Hefei Institutes of Physical Science to drive its research and development efforts. The company is privately held and continues to expand its portfolio of targeted therapies to address significant unmet medical needs in the global healthcare market.